Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Timothy Jay Price
Based on 4 articles published since 2009
(Why 4 articles?)

Between 2009 and 2019, Timothy Price wrote the following 4 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. 2017

Segelov, Eva / Lordick, Florian / Goldstein, David / Chantrill, Lorraine A / Croagh, Daniel / Lawrence, Ben / Arnold, Dirk / Chau, Ian / Obermannova, Radka / Price, Timothy Jay. ·a Department of Oncology , Monash Medical Centre and Monash University , Melbourne , Australia. · b Department of Oncology, University Cancer Center Leipzig , University Medicine Leipzig , Leipzig , Germany. · c Department of Oncology, Nelune Cancer Centre , Prince of Wales Hospital and University of New South Wales , Sydney , Australia. · d Department of Oncology , The Kinghorn Cancer Centre and University of Western Sydney , Sydney , Australia. · e Department of Oncology , University of Auckland , Auckland , New Zealand. · f Department of Oncology , Instituto CUF de Oncologia , Lisbon , Portugal. · g Department of Oncology , Royal Marsden Hospital , London & Surrey , UK. · h Department of Comprehensive Cancer Care , Masaryk Memorial Cancer Institute , Brno , Czech Republic. · i Queen Elizabeth Hospital and Lyell McEwin Hospital , Adelaide , Australia. ·Expert Rev Anticancer Ther · Pubmed #28817982.

ABSTRACT: INTRODUCTION: Despite recent progress, the outlook for most patients with pancreatic cancer remains poor. There is variation in how patients are managed globally due to differing interpretations of the evidence, partly because studies in this disease are challenging to undertake. This article collates the evidence upon which current best practice is based and offers an expert opinion from an international faculty on how latest developments should influence current treatment paradigms. Areas covered: Optimal chemotherapy for first and subsequent lines of therapy; optimal management of locally advanced, non-metastatic cancer including the role of neoadjuvant chemo(radio)therapy, current evidence for adjuvant chemotherapy, major advances in pancreatic cancer genomics and challenges in supportive care particularly relevant to patients with pancreatic cancer. For each section, literature was reviewed by comprehensive search techniques, including clinical trial websites and abstracts from international cancer meetings. Expert commentary: For each section, a commentary is provided. Overall the challenges identified were: difficulties in diagnosing pancreatic cancer early, challenges for performing randomised clinical trials in all stages of the disease, some progress in systemic therapy with new agents and in identifying molecular subtypes that may be clinically relevant and move towards personalized therapy, but still, pancreatic cancer remains a very poor prognosis cancer with significant palliative care needs.

2 Review Advances in Molecular Pathology and Treatment of Periampullary Cancers. 2016

Chandrasegaram, Manju D / Chen, John W / Price, Timothy J / Zalcberg, John / Sjoquist, Katrin / Merrett, Neil D. ·From the *NHMRC Clinical Trials Centre; †Department of Surgery, The Prince Charles Hospital, Brisbane; ‡Department of Surgery, Flinders Medical Centre; §Queen Elizabeth Hospital, Adelaide; ∥University of Adelaide, South Australia; ¶School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne; #Cancer Care Centre, Department of Medical Oncology, St George Hospital; **Department of Surgery, Bankstown Hospital; and ††Division of Surgery, University of Western Sydney, Sydney, Australia. ·Pancreas · Pubmed #26348463.

ABSTRACT: OBJECTIVES: Periampullary cancers (PACs) include the following 4 traditional anatomic subtypes: pancreatic, ampullary, biliary, or duodenal cancers. This review was performed to highlight recent advances in the genomic and molecular understanding of each PAC subtype and the advances in chemotherapeutic and molecular trials in these cancer subtypes. RESULTS: Recent advances have highlighted differences in the genomic and molecular features within each PAC subtype. Ampullary cancers can now be further defined accurately into their intestinal and pancreatobiliary subtypes using histomolecular profiling. K-ras mutation, which occurs in most pancreatic cancers, is found to occur less frequently in ampullary (42%-52%), biliary (22%-23%), and duodenal cancers (32%-35%), suggesting crucial differences in targetable mutations in these cancer subtypes.Ampullary cancers of intestinal subtype and duodenal cancers seem to share similarities with colorectal cancer, given that they respond to similar chemotherapeutic regimens. This has potential implications for clinical trials and treatment selection, where PACs are often considered together. CONCLUSIONS: Future trials should be designed in view of our increased understanding of the different anatomic and histomolecularly profiled subtypes of PAC cancers, which respects their individual molecular characteristics, phenotype, and response to treatment.

3 Clinical Trial Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. 2012

Millward, Michael / Price, Timothy / Townsend, Amanda / Sweeney, Christopher / Spencer, Andrew / Sukumaran, Shawgi / Longenecker, Angie / Lee, Lonnie / Lay, Ana / Sharma, Girish / Gemmill, Robert M / Drabkin, Harry A / Lloyd, G Kenneth / Neuteboom, Saskia T C / McConkey, David J / Palladino, Michael A / Spear, Matthew A. ·Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia. ·Invest New Drugs · Pubmed #22080430.

ABSTRACT: PURPOSE: Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat. Thus, in this study in vitro studies assessed the potential utility of combining marizomib and vorinostat, followed by a clinical trial with the objectives of assessing the recommended phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD), safety and preliminary anti-tumor activity of the combination in patients. EXPERIMENTAL DESIGN: Combinations of marizomib and vorinostat were assessed in vitro. Subsequently, in a Phase 1 clinical trial patients with melanoma, pancreatic carcinoma or Non-small Cell Lung Cancer (NSCLC) were given escalating doses of weekly marizomib in combination with vorinostat 300 mg daily for 16 days in 28 day cycles. In addition to standard safety studies, proteasome inhibition and pharmacokinetics were assayed. RESULTS: Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma. In the clinical trial, 22 patients were enrolled. Increased toxicity was not seen with the combination. Co-administration did not appear to affect the PK or PD of either drug in comparison to historical data. Although no responses were demonstrated using RECIST criteria, 61% of evaluable patients demonstrated stable disease with 39% having decreases in tumor measurements. CONCLUSIONS: Treatment of multiple tumor cell lines with marizomib and vorinostat resulted in a highly synergistic antitumor activity. The combination of full dose marizomib with vorinostat is tolerable in patients with safety findings consistent with either drug alone.

4 Article Pancreatic cancer epidemiology and survival in an Australian population. 2009

Luke, Colin / Price, Timothy / Karapetis, Christos / Singhal, Nimit / Roder, David. ·Epidemiology Branch, South Australian Department of Health, Adelaide, South Australia. jowen@cancersa.org.au ·Asian Pac J Cancer Prev · Pubmed #19640175.

ABSTRACT: South Australian registry data were used to explore age-standardised incidence and mortality rates and case survivals for pancreatic cancer during 1977 to 2006. Disease-specific survivals were investigated using Kaplan-Meier estimates and Cox proportional hazards regression. While annual incidence and mortality rates were relatively stable among males during 1983-2006, they were 14% and 17% lower respectively than for the 1977-82 baseline. A converse non-significant secular trend was suggested in females, in that incidence in 1989-2006 was 10% higher than in 1977-88, with a corresponding 9% increase in mortality. As a result, male to female incidence rate ratios decreased from 1.73:1 in 1977-82 to about 1.34:1 in 2001-06. One-year survival was 18.0% but this figure decreased to 3.6% at five years. Higher survivals were evident for more recent diagnostic periods, with one-year survival increasing from 14.3% in 1977-88 to 23.9% in 2001-06. Multivariable proportional hazards regression indicated that case fatality was higher in the older age groups and lower for neuroendocrine than other histology types, patients from high and mid-high than lower socio-economic areas, and for more recent diagnostic periods. The differences by diagnostic period, socio-economic status and histology type applied both to the age range less than 60 years and between 60 and 79 years, but were not evident in older patients. The divergent secular trends in incidence and mortality in males and females and associated decreases in male to female rate ratio are consistent with trends in the USA and likely reflect differences in historic tobacco smoking trends by sex. While survival at five years from diagnosis is still only about 5%, patients are living longer with more surviving one year or more, probably due to gains in treatment and potentially in diagnostic technology.